Blog
Could This SPAC Be the Best Mortgage Stock to Buy Now?
Several mortgage originators have gone public in the past six months or so, and with record-high refinancing volume and a surge in purchase mortgage applications, it's not surprising that these
1 Apartment Stock That Could Be a Huge Long-Term Winner
AvalonBay Communities (NYSE: AVB) is one of the largest residential REITs in the market, with impressive properties in some of the highest-cost U.S. markets. However, in this Fool Live video clip
This Blue Chip Stock Could Have a Great Summer
It's shaping up to be the summer of the great reopening in 2021, and some stocks could be big winners as the U.S. gets back to normal. In this Fool Live video clip, recorded on June 14, Fool.com
Warren Buffett's Berkshire Hathaway Likes Kroger Stock and You Should, Too
Following Kroger's (NYSE: KR) better-than-expected fiscal first-quarter results earlier this month, the company is announcing a double-digit increase to its dividend. The significant increase
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
Treating rare diseases can't be profitable because there are too few patients, right? As it turns out, targeting uncommon and severe illnesses can be a brilliant business decision -- especially if
Fannie Mae and Freddie Mac Shareholders Lose in Court; Here's What That Means for the Stock
June 23 was a big day in the mortgage market as the Supreme Court decided two issues that will weigh heavily on the future of Fannie Mae (OTC: FNMA) and Freddie Mac (OTC: FMCC). The Supreme Court
What Does Palantir Actually Do? And Is It a Good Investment?
Few companies are as difficult for non-techies to understand as Palantir (NYSE: PLTR). The software company was started in the aftermath of Sept. 11 and focused on providing counterterrorism
Alaska Airlines Exits the Top U.S. Airline Route
The COVID-19 pandemic has forced U.S. airlines to make tough decisions about their route networks. Many carriers are shoring up the strongest parts of their route networks and boosting capacity to
Winnebago's Earnings Call: 3 Big Takeaways
Winnebago Industries (NYSE: WGO) isn't fooling itself. The RV giant knows that much of its recent soaring sales growth is just temporary. Its more than 100% demand spike in the fiscal third quarter
Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?
When most of a company's eggs are in one basket, it's entirely reasonable to want to sell your shares if you find out there's a big hole in the bottom.
Such is the case with CureVac (NASDAQ: CVAC)
Is 23andMe a Buy at $11?
Freshly listed on the NASDAQ following a business combination with VG Acquisition Corp, a special purpose acquisition company (SPAC), the consumer genetic-testing maven 23andMe (NASDAQ: ME) is at
Better Buy: Amazon vs. Walmart
Walmart (NYSE: WMT) was struggling to keep pace with Amazon (NASDAQ: AMZN) when Doug McMillon became the retail giant's CEO in 2014. Its superstores were becoming showrooms for Amazon's online
How Big Will E-Commerce Get By 2025?
E-commerce has grown dramatically in recent years, but the vast majority of retail sales still take place the old-fashioned way, in stores. In this Fool Live clip, recorded on June 15, Millionacres
Will This 2020 Biotech IPO Crush the Market This Year?
Cutting-edge pharma Legend Biotech (NASDAQ: LEGN) burst onto the scene at the 2017 American Society of Clinical Oncology (ASCO) meeting with fantastic early clinical trial results for its multiple
Don't Let These 4 Social Security Surprises Ruin Your Retirement
Many people overestimate what Social Security benefits can do for them in their later years. If you're one of them, you could find yourself with a financial shortfall in retirement.
It's best to
Got $5,000? These 3 Stocks Are Ridiculously Cheap Buys
If you have $5,000 available to invest in stocks, there are some great options out there for you. The three stocks I have listed below are underrated investments and are trading at low earnings
Why Johnson & Johnson Is Trashing 60 Million Doses of Its COVID Vaccine
Johnson & Johnson (NYSE: JNJ) hasn't become the major player in the COVID-19 vaccine market that many expected it to be, in large part because of manufacturing issues at a contractor's facility
Can Clorox Transform Its Pandemic Boost into Permanent Gains?
The ongoing COVID-19 pandemic has devastated countless businesses alongside its obvious human cost. But there are those companies that have benefited because their products were in high demand
Dump FAANG and Buy These 3 Cheaper Growth Stocks Instead
Buying shares of top tech stocks Facebook, Apple, Amazon, Netflix, and Alphabet (Google) -- otherwise known as FAANG -- would have earned great returns in the past. But now, with their valuations
3 Reasons a 401(k) Loan Is Better Than an Early Withdrawal
When you need money in a pinch, there's always the option to go to a bank or lending institution and ask for a loan. But why have to beg for a loan when you have money sitting in your very own
3 Reasons to Buy Johnson & Johnson, and 1 Reason to Sell
Many investors are aware of the reasons to invest in Johnson & Johnson (NYSE: JNJ). It is big, diversified, and sports one of the healthier dividend yields in the Dow Jones Industrial Average (DJIND
Here's How Much You Can Make From Investing Your Tax Return Every Year
According to the IRS, the average tax refund this year has been $2,775, just 0.3% higher than last year's total of $2,767. While many people may use that money to pay down bills or end up spending
Better Cannabis Stock: Tilray vs. Village Farms
A good way to maximize your odds of success when investing in the cannabis industry is by buying shares of low-cost producers. Profitability is hard to come by in the sector, especially in the
Could Biogen's Big Win With Aduhelm Become a Big Liability?
Biogen's (NASDAQ: BIIB) stock roared on June 7 after the unexpected approval of its Alzheimer's disease drug, Aduhelm. Now, the entire biopharma industry is alight with criticism of the U.S. Food
Should You Buy Onion Global After Its Busted IPO?
Onion Global (NYSE: OG) has been one of the worst tech IPOs of 2021. The Chinese e-commerce company went public at $7.25 per share in early May, closed at $7 on the first day, and is now only worth


